Free Trial
CVE:PTF

Pender Growth Fund (PTF) Stock Price, News & Analysis

Pender Growth Fund logo
C$13.54 -0.20 (-1.46%)
As of 07/2/2025 11:05 AM Eastern

About Pender Growth Fund Stock (CVE:PTF)

Key Stats

Today's Range
C$13.54
C$13.55
50-Day Range
C$9.85
C$14.59
52-Week Range
C$9.29
C$14.99
Volume
400 shs
Average Volume
2,983 shs
Market Capitalization
C$98.17 million
P/E Ratio
2.19
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PTF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pender Growth Fund and its competitors with MarketBeat's FREE daily newsletter.

PTF Stock News Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
See More Headlines

PTF Stock Analysis - Frequently Asked Questions

Pender Growth Fund's stock was trading at C$11.19 at the start of the year. Since then, PTF stock has increased by 21.0% and is now trading at C$13.54.
View the best growth stocks for 2025 here
.

Shares of PTF stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pender Growth Fund investors own include Armata Pharmaceuticals (ARMP), BioCardia (BCDA), Bristol Myers Squibb (BMY), Range Cancer Therapeutics ETF (CNCR), Inovio Pharmaceuticals (INO), Insight Select Income Fund (INSI) and Protalix BioTherapeutics (PLX).

Industry, Sector and Symbol

Stock Exchange
CVE
Industry
Asset Management
Sub-Industry
N/A
Current Symbol
CVE:PTF
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
2.19
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
C$44.92 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$49.38 million
Cash Flow
C$1.62 per share
Price / Cash Flow
8.35
Book Value
C$15.08 per share
Price / Book
0.90

Miscellaneous

Free Float
N/A
Market Cap
C$98.17 million
Optionable
Not Optionable
Beta
0.56
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (CVE:PTF) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners